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of radiation sensitivity. A subset of these candidate 
molecules could be validated having an impact in clinical 
outcome of radiation therapy treated HNSCC patients.  
 
Conclusion: Our study demonstrates that multi-level 
radiation systems biology allows gaining deeper insights into 
chief mechanisms of radiation sensitivity, thereby paving the 
way for targeted individualised therapy approaches in 
radiation oncology. 
 
Debate: This house believes that progress in the treatment 
of locally advanced NSCLC will come from:  
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A large proportion of non-small cell lung cancer (NSCLC) 
patients are diagnosed with locally advanced (stage III) 
disease. For this patient group the treatment of choice is 
definitive concurrent chemoradiation (CCRT). CCRT results in 
an improved overall survival (OS) compared to sequential 
chemoradiotherapy or radiotherapy alone because of 
improved locoregional control. However 2-year OS rates of 
30-35% are still poor because many patients develop 
locoregional failures (about 30%) and distant metastases 
(about 40%)1. Currently locally advanced NSCLC patients 
selected for CCRT have FDG-PET scanning and imaging of the 
brain (MRI or CT scan). Despite this brain imaging with the 
present chemotherapy regimens used we are faced with the 
problem of brain metastases in about 10% of the patients 
within 1 year after chemoradiation.  
In several chemoradiation studies it was reported that the 
Gross Tumor Volume is correlated with OS. This is rational 
since the tumor volume represents the number of clonogenic 
tumor cells that needs to be eradicated. To improve 
locoregional control the dose prescription could be escalated 
taking into account the individual Gross Tumor Volumes and 
tolerances using image guided adaptive Intensity Modulated 
Radiotherapy (IMRT). However there are radiation oncologists 
who challenge the usefulness of RT dose escalation and 
intensification in patients with stage III NSCLC. The outcome 
of a randomized phase III trial, RTOG 06171, revealed that 
NSCLC patients within the 74 Gy arm given in 7.5 weeks had 
worse local control and significantly worse overall survival as 
compared to the patients treated to 60 Gy arm in 6 weeks2. 
Patients in all study arms received two additional cycles of 
consolidation chemotherapy ± cetuximab. So the obvious 
question is: How do we continue?  
Dose escalation with prolonged overall treatment time in 
NSCLC has previously been proven disappointing because of 
accelerated repopulation3.In an individual patient data meta-
analysis in patients with non-metastatic lung cancer, which 
included trials comparing modified radiotherapy with 
conventional radiotherapy, a significant OS benefit from 
accelerated or hyperfractionated radiotherapy was reported4. 
Another issue is the use of consolidation chemotherapy after 
concurrent chemoradiation. In the RTOG 0617 trial the 
increase in mortality started < 3 months after randomization 
during the period of consolidation paclitaxel-carboplatin 
chemotherapy. Generally taxanes given after RT increases 
toxicity and the combination of high dose to the heart and 
consolidation taxane-based chemotherapy might have caused 
toxic deaths and biased the outcome. RT dose intensification 
while using modern image guided adaptive IMRT and 
accelerated schemes is an important area of ongoing clinical 
research and should not be discontinued.  
In Stereotactic Ablative Body Radiotherapy (SABR) much 
higher biologically equivalent doses are delivered compared 
to conventionally fractionated RT (typically EQD2 of 70-85 
Gy), and has generated outstanding tumor control in early 
stage NSCLC. For SABR a significant dose–response 
relationship was observed for prescription EQD2 of 105 Gy or 
more (2-year LC 96%) or of less than 105 Gy (2-year LC 85%)5. 
Tumor size and overall treatment time were also important 
factors influencing outcome.  
The tumor control probability of SBRT (small tumor volume) 
and conventionally fractionated chemoradiation (large tumor 
volume) were successfully described in a single model6 
suggesting that a dose-response relation in NSCLC does exist.  
Recently there is a growing interest in genetic profiles that 
predict a patient’s response to radiotherapy, because severe 
toxicity in a minority of patients limits the doses that can be 
safely given to the majority. Recent progress in genotyping 
raises the possibility of genome-wide studies. If we know the 
normal tissue reactions to radiotherapy by genotype we will 
really be able to tailor the individual radiation dose.  
In conclusion: Besides the unsolved problem of the 
occurrence of distant metastases there is room for 
improvement of locoregional control in locally advanced 
NSCLC patients treated with chemoradiation. In the era of 
personalized treatment, radiotherapy dose intensification 
using image guided adaptive IMRT could be directed towards 
individual tumor volumes and tolerances. RT dose 
intensification while using accelerated schemes is an 
important area of ongoing clinical research  
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About one third of patients with non-small cell lung cancer 
(NSCLC) present with locoregional disease extension in either 
the mediastinum (T4) or the mediastinal lymph nodes (N2/3). 
Apart from a fraction in which resection after induction 
therapy is sometimes considered, selected patients with 
stage 3 are candidate for a so-called definitive 
radiochemotherapy, administered either sequentially or 
concomitantly. Despite staging with PET-CT scan and 
endosonographic mapping of mediastinal lymph nodes and 
notwithstanding a patient selection for this radical 
treatment, the outcome in stage 3 is nevertheless moderate 
with a median survival of 2 years [1]. Progression occurs after 
a median of 10 months and is due to local relapse or distant 
metastasis in 30 and 45% of cases, respectively. Any advance 
in the outcome in stage 3 NSCLC will hence depend on 
improvements in systemic therapy directed at distant 
metastasis. The past 10 years have seen important changes in 
the paradigm of treatment in selected patients with 
advanced NSCLC, in whom platinum-based doublet 
chemotherapy used to be the standard of care. The discovery 
of drugable genomic alterations has introduced precision 
medicine in oncology. Patients whose NSCLC harbour either 
an activating EGFR mutation, EML-ALK translocation or ROS1 
amplification are now routinely treated with oral small 
molecule kinase inhibitors of the 1st, 2nd and 3rd generation 
instead of chemotherapy, with a significant improvement in 
outcome and a substantial impact on quality of life. Similar, 
although less pronounced effects have been observed when 
adding monoclonal antibodies directed at targets associated 
with angiogenesis or cell growth to the chemotherapy 
backbone. Unfortunately, the incorporation of these 
